secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001213900-23-055881
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals receives Nasdaq extension to regain minimum equity compliance; equity $1.44M vs $2.5M required
--------------------------------------------------------------------------------

- Nasdaq granted extension until August 21, 2023 to file Form 10-Q to show compliance with Listing Rule 5550(b)(1).
- As of March 31, 2023, stockholders' equity was $1,439,848, below the $2,500,000 minimum.
- Compliance plan submitted June 28, 2023; expects to regain compliance upon Q2 10-Q filing.
- If compliance not regained, Company can request a hearing; listing may be suspended or delisted.
- Company monitoring equity and may consider further options to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023055881/0001213900-23-055881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023055881/ea181585-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-055881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer